Group One Trading, L.P. Aprea Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$2.4 Billion
Q3 2024

Shares

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q4 2022 Feb 09, 2023	BUY	$0.32 - $15.2 $4,160 - $197,600	13,000 Added 41.93%	44,003 $14,000
Q3 2022 Nov 09, 2022	SELL	$0.71 - $13.6 $1,278 - $24,480	-1,800 Reduced 5.49%	31,003 $20,000
Q2 2022 Aug 11, 2022	SELL	$0.62 - $1.94 $12,586 - $39,383	-20,301 Reduced 38.23%	32,803 $24,000
Q1 2022 May 12, 2022	SELL	$1.59 - $3.16 $26,610 - $52,885	-16,736 Reduced 23.96%	53,104 $99,000
Q4 2021 Feb 11, 2022	SELL	$2.87 - $5.58 $8,612 - $16,745	-3,001 Reduced 4.12%	69,840 $200,000
Q3 2021 Nov 12, 2021	BUY	$3.43 - $5.63 $66,528 - $109,199	19,396 Added 36.29%	72,841 $372,000
Q2 2021 Aug 10, 2021	BUY	$4.05 - $5.5 $212,402 - $288,447	52,445 Added 5244.5%	53,445 $261,000
Q1 2021 May 12, 2021	BUY	$4.73 - $8.15 $4,730 - $8,150	1,000 New	1,000 $5,000

Others Institutions Holding APRE

# of Institutions

2

Shares Held

899

Call Options Held

0

Put Options Held

0

Nbc Securities, Inc. Birmingham, AL

899
Shares

$2,589
0.0% of portfolio
Concourse Financial Group Securities, Inc. Birmingham, AL

0
Shares

$0
0.0% of portfolio

About Aprea Therapeutics, Inc.

Ticker APRE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Description
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products...

More about APRE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.